A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age
Latest Information Update: 30 Apr 2025
At a glance
- Drugs V 114 (Primary) ; Varicella vaccine-GlaxoSmithKline (Primary) ; 13-Valent pneumococcal conjugate vaccine; Hepatitis A vaccine; Measles mumps and rubella virus vaccine; PCV 20
- Indications Chickenpox
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GSK
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 9 Feb 2027 to 2 Feb 2027.
- 06 Mar 2025 New trial record